USPTO serial 88051051
HARVEST ONE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BEN, LINDSEY HEATHER
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with HARVEST ONE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas J. Romano
Thomas J. Romano Kolitch Romano Dascenzo Gates LLC621 SW Morrison Street #1100Portland, OR 97205UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | cosmetics with cannabinoid content; cannabis preparations and derivative products in the form of personal care preparations for the body, namely, creams, oils, emollients, ointments, rubs, lotions, and salves | ACTIVE | — |
| 005 | pharmaceuticals for the relief of pain and treatment of palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritis, neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, and pain, movement disorders, glaucoma, asthma, hypertension, mental illness, namely, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, and dementia, inflammatory diseases, namely, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, and inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; pharmaceuticals containing one or more cannabinoids as the active ingredient; pharmaceuticals, nutraceuticals and consumer products containing cannabis, cannabinoids or cannabis compounds; cannabinoids or cannabis compounds for use in pharmaceuticals; cannabis compounds, namely, medicines containing a tetrahydrocannabinol extract; cannabis based pharmaceuticals and nutraceuticals; narcotics for medical use; nutritional and dietary supplements for general health and well-being; pharmaceutical preparations for the relief of pain and treatment of palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritis, neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, and pain, movement disorders, glaucoma, asthma, hypertension, mental illness, namely, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, and dementia, inflammatory diseases, namely, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, and inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; pharmaceutical preparations containing one or more cannabinoids as the active ingredient; medicines containing a tetrahydrocannabinol extract; medicines derived from cannabis; nutraceuticals, plants, dried plant material, seeds and medicines derived from the cannabis plant; products, plants, dried plant material, seeds and medicines derived from and/or related to the cannabis plant, namely, anti-inflammatories, analgesics, sedatives, appetite stimulants, anti-nauseants, intraocular pressure reducers, anti-tumors, antioxidants, antidepressants and antihypertensives | ACTIVE | — |
| 031 | plant seeds; agricultural seeds; cannabis products, namely, hashish, cannabis, cannabis seeds; cannabis seeds and cannabis plants; marihuana; medical marihuana; seeds for planting; raw and unprocessed seeds; natural plants; seeds; plants; dried plants | ACTIVE | — |
| 035 | operation of a dispensary; online operation of a dispensary; mail order medical marihuana clubs; retail and wholesale sales of medical marihuana and seeds; retail and wholesale store reward program; membership services, namely, the operation and maintenance of a membership organization for retail and wholesale stores in the field of medical marihuana; dispensing cannabis products, namely, hashish, cannabis, cannabis seeds, pharmaceuticals and nutraceuticals containing cannabis, cannabinoids or cannabis compounds; dispensing pharmaceutical products containing cannabis; dispensing cannabis; dispensing marihuana; sale of medical marihuana and cannabis extracts; sale of medical marihuana and cannabis extracts, namely, hashish and cannabis resins; dispensing medicinal marijuana and cannabis based products, namely, cannabis based pharmaceuticals and nutraceuticals; retail and wholesale sales of cannabis; providing identification cards for use in connection with customer loyalty, rewards, bonus points, and discount programs | ACTIVE | — |
| 036 | Investment of funds; investment of funds in the field of cannabis and medical marijuana; capital investment; capital investment in the field of cannabis and medical marijuana; services rendered in connection with the provision of commercial financing | ACTIVE | — |
| 042 | research services in the field of cannabis and medical marihuana; product development services in the field of cannabis and medical marihuana; operation of a computer database in the field of medical marihuana; operation of a website that provides online social networking; operation of a website containing information in the field of medical marihuana; research services, namely, research of new products for others; research services in the area of cannabis, namely, marihuana; research services in the area of cannabis, namely, medical marihuana; product development services; product development services in the area of cannabis; product development services in the area of cannabis, namely, marihuana; product development services in the area of cannabis, namely, medical marihuana; operation of a website containing information in the field of marihuana and cannabis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Harvest One Cannabis Inc.
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 031
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 042
- Similar marks named HARVEST ONE
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 12, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 12, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 12, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 28, 2022 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 28, 2022 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 28, 2022 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 28, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Oct 6, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 6, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 6, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 6, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 25, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 25, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 25, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 25, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 25, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 1, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 1, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 1, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 20, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 7, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 7, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 7, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 22, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 22, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 18, 2021 | ALIE | ASSIGNED TO LIE | — |
| Mar 15, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 15, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Sep 15, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Sep 15, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Aug 31, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Aug 21, 2020 | ALIE | ASSIGNED TO LIE | — |
| Jan 24, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 24, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 24, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 31, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 31, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 31, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 1, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 1, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 1, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 25, 2019 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Jun 24, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 5, 2019 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Jan 22, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 28, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 7, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 30, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 27, 2018 | NWAP | NEW APPLICATION ENTERED | — |